Vanguard Group Inc. Purchases 1,261,920 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU)

Vanguard Group Inc. increased its position in Caribou Biosciences, Inc. (NASDAQ:CRBU) by 49.3% in the 3rd quarter, Holdings Channel reports. The firm owned 3,822,151 shares of the company’s stock after buying an additional 1,261,920 shares during the quarter. Vanguard Group Inc.’s holdings in Caribou Biosciences were worth $18,270,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. Swiss National Bank raised its stake in shares of Caribou Biosciences by 8.0% in the first quarter. Swiss National Bank now owns 57,000 shares of the company’s stock worth $523,000 after acquiring an additional 4,200 shares during the last quarter. ProShare Advisors LLC lifted its holdings in Caribou Biosciences by 22.1% during the 1st quarter. ProShare Advisors LLC now owns 15,766 shares of the company’s stock worth $145,000 after buying an additional 2,856 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Caribou Biosciences by 2,754.9% during the 1st quarter. JPMorgan Chase & Co. now owns 515,758 shares of the company’s stock worth $4,735,000 after buying an additional 497,692 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Caribou Biosciences by 108.2% in the 1st quarter. Bank of New York Mellon Corp now owns 141,262 shares of the company’s stock valued at $1,297,000 after buying an additional 73,427 shares during the last quarter. Finally, MetLife Investment Management LLC increased its stake in shares of Caribou Biosciences by 311.7% in the 1st quarter. MetLife Investment Management LLC now owns 31,003 shares of the company’s stock valued at $285,000 after buying an additional 23,472 shares during the period. Institutional investors and hedge funds own 77.51% of the company’s stock.

Caribou Biosciences Stock Performance

Shares of NASDAQ:CRBU opened at $4.20 on Monday. The company has a 50 day moving average price of $6.10 and a two-hundred day moving average price of $5.47. The company has a market capitalization of $379.34 million, a PE ratio of -2.90 and a beta of 2.47. Caribou Biosciences, Inc. has a 52 week low of $3.44 and a 52 week high of $8.59.

Caribou Biosciences (NASDAQ:CRBU) last announced its earnings results on Monday, March 11th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.17). The company had revenue of $3.56 million for the quarter, compared to analyst estimates of $5.17 million. Caribou Biosciences had a negative return on equity of 31.06% and a negative net margin of 296.05%. On average, sell-side analysts forecast that Caribou Biosciences, Inc. will post -1.76 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright boosted their price objective on Caribou Biosciences from $23.00 to $24.00 and gave the stock a “buy” rating in a report on Tuesday, March 19th.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.